ONCOLOGY Vol 35, Issue 4 | Oncology

Around the Practice: Relapsed/Refractory HER2+ Metastatic Breast Cancer

April 22, 2021

Clinical Update

Experts discusses the treatment of patients with HER2-positive breast cancer in a virtual CancerNetwork® Around the Practice presentation,“Relapsed/Refractory HER2+ Metastatic Breast Cancer,” held January 21, 2021, and moderated by Adam M. Brufsky, MD, PhD.

Treatment Considerations for Transplant-Ineligible Multiple Myeloma

April 22, 2021

Review Article

Radowan A. Elnair, MD, and Sarah A. Holstein, MD, PhD, review literature regarding progress in the management of the transplant-ineligible multiple myeloma in an article published in the journal ONCOLOGY®.

How to Radiologically Assess and Follow Response After Treatment of Hepatocellular Carcinoma

April 21, 2021

Clinical Quandaries

A thought-provoking installment of Clinical Quandaries is presented by Alejandro Gabutti, MD; and Tommaso Cascella, MD, of a 36-year-old patient with hepatitis C virus-related cirrhosis and a subsequent diagnosis of hepatocellular carcinoma.

Messenger RNA Vaccines: Beckoning of a New Era in Cancer Immunotherapy

April 21, 2021

Review Article

A review of mRNA vaccine technology by ONCOLOGY® editorial board member Mehmet Sitki Copur, MD, FACP, explains the basis for progress in this field and reviews a number of new trials using this technology.

Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer

April 19, 2021


ONCOLOGY® editorial board member E. David Crawford, MD, and colleagues, propose a new model for guiding the treatment of prostate cancer that focuses on a “transitional state,” which occurs during the interval of progression to metastatic castration-resistant prostate cancer.

Messenger RNA: A Technology of the Moment

April 16, 2021


In his "Letter to the Readers", co-editor-in-chief of the journal ONCOLOGY Howard S. Hochster, MD, reviews the development of mRNA technology, especially as it applies to vaccines against COVID-19.